Abstract

Blood metabolites of the tryptophan pathway were found to be associated with kidney function and disease in observational studies. In order to evaluate causal relationship and direction, we designed a study using a bidirectional Mendelian randomization approach. The analyses were based on published summary statistics with study sizes ranging from 1,960 to 133,413. After correction for multiple testing, results provided no evidence of an effect of metabolites of the tryptophan pathway on estimated glomerular filtration rate (eGFR). Conversely, lower eGFR was related to higher levels of four metabolites: C-glycosyltryptophan (effect estimate = − 0.16, 95% confidence interval [CI] (− 0.22; − 0.1); p = 9.2e−08), kynurenine (effect estimate = − 0.18, 95% CI (− 0.25; − 0.11); p = 1.1e−06), 3-indoxyl sulfate (effect estimate = − 0.25, 95% CI (− 0.4; − 0.11); p = 6.3e−04) and indole-3-lactate (effect estimate = − 0.26, 95% CI (− 0.38; − 0.13); p = 5.4e−05). Our study supports that lower eGFR causes higher blood metabolite levels of the tryptophan pathway including kynurenine, C-glycosyltryptophan, 3-indoxyl sulfate, and indole-3-lactate. These findings aid the notion that metabolites of the tryptophan pathway are a consequence rather than a cause of reduced eGFR. Further research is needed to specifically examine relationships with respect to chronic kidney disease (CKD) progression among patients with existing CKD.

Highlights

  • Blood metabolites of the tryptophan pathway were found to be associated with kidney function and disease in observational studies

  • We evaluated nine metabolites of the tryptophan pathway based on non-targeted measurements in a similar study, and identified C-glycosyltryptophan to be associated with estimated glomerular filtration rate (eGFR) and chronic kidney disease (CKD), as well as with prospective endpoints of eGFR decline, incident CKD and E­ SKD16

  • The search for relevant published studies focused on genome-wide association studies (GWAS) of these metabolites

Read more

Summary

Introduction

Blood metabolites of the tryptophan pathway were found to be associated with kidney function and disease in observational studies. Our study supports that lower eGFR causes higher blood metabolite levels of the tryptophan pathway including kynurenine, C-glycosyltryptophan, 3-indoxyl sulfate, and indole-3-lactate. These findings aid the notion that metabolites of the tryptophan pathway are a consequence rather than a cause of reduced eGFR. We evaluated nine metabolites of the tryptophan pathway based on non-targeted measurements in a similar study, and identified C-glycosyltryptophan ( known as C-mannosyltryptophan) to be associated with eGFR and CKD, as well as with prospective endpoints of eGFR decline, incident CKD and E­ SKD16

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call